Literature DB >> 1803987

Antimicrobial agent therapy for Pseudomonas aeruginosa.

J A Korvick1, V L Yu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1803987      PMCID： PMC245354          DOI： 10.1128/AAC.35.11.2167

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  84 in total

1.  Bacteremic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area.

Authors:  C S Bryan; K L Reynolds
Journal:  Am Rev Respir Dis       Date:  1984-05

Review 2.  Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.

Authors:  B E Kreger; D E Craven; P C Carling; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

Review 3.  Nosocomial infections due to Pseudomonas aeruginosa: review of recent trends.

Authors:  A Cross; J R Allen; J Burke; G Ducel; A Harris; J John; D Johnson; M Lew; B MacMillan; P Meers
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

4.  Broth microdilution testing of Pseudomonas aeruginosa and aminoglycosides: need for employing dilutions differing by small arithmetic increments.

Authors:  B F Woolfrey; J M Fox; R T Lally; C O Quall
Journal:  J Clin Microbiol       Date:  1982-10       Impact factor: 5.948

5.  Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa.

Authors:  J J Zuravleff; V L Yu; R B Yee; M K Zaphyr; W Diven; F B Taylor
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.

Authors:  D J Winston; R C Barnes; W G Ho; L S Young; R E Champlin; R P Gale
Journal:  Am J Med       Date:  1984-09       Impact factor: 4.965

7.  Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.

Authors:  M J Chusid; S D Davis; L D Sarff
Journal:  J Lab Clin Med       Date:  1983-03

Review 8.  Infections caused by Pseudomonas aeruginosa.

Authors:  G P Bodey; R Bolivar; V Fainstein; L Jadeja
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

9.  Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.

Authors:  M P Reyes; A M Lerner
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

10.  Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.

Authors:  J J Zuravleff; V L Yu; R B Yee
Journal:  J Lab Clin Med       Date:  1983-06
View more
  15 in total

1.  Incidence and mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa serotype O11 isolates.

Authors:  M Kettner; P Milosovic; M Hletková; J Kallová
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

2.  In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.

Authors:  F Tessier; C Quentin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

3.  In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.

Authors:  R C Owens; M A Banevicius; D P Nicolau; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.

Authors:  V Dubois; C Arpin; M Melon; B Melon; C Andre; C Frigo; C Quentin
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 5.  Aminoglycoside adaptive resistance: importance for effective dosage regimens.

Authors:  M L Barclay; E J Begg
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.

Authors:  J A Karlowsky; M H Saunders; G A Harding; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model.

Authors:  B J McGrath; K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.

Authors:  K Weiss; J R Lapointe
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  E F Marley; C Mohla; J M Campos
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

Review 10.  Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance.

Authors:  L R Peterson; C J Shanholtzer
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.